Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Check out the full piece: #ObesityCare #GLP1 #ChronicDisease #ValueBasedCare To view or add a comment, sign in Ilant Health founder and CEO Elina Onitskansky, alongside Bryan Sivak (former HHS CTO), just published an op-ed in Fortune tackling a binary problem in the GLP-1 debate: cover everything, or cover nothing
For the primary composite outcome and secondary hierarchical outcomes, the threshold for two-sided statistical significance was set to 0.0322 (one-sided level 0.00161) using Lan-DeMets alpha spending function, which allows to adjust significance levels as data were reviewed for the interim analysis, reducing the chance of false positive results
FDA-approved tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight management, is a clear, colorless to slightly yellow solution
The MASH trials main goals are to improve liver fibrosis and resolve steatohepatitis without worsening either condition in people with MASH
US$ 23.37
US$ 28.14
US$ 20.44
US$ 27.59
US$ 26.47
US$ 29.63
US$ 27.37
